News

European Medical Journal4d
Rilzabrutinib Offers Hope for Patients with Refractory Urticaria
CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of ...
Medical Dialogues4d
Rilzabrutinib could be effective treatment option in individuals with moderate to severe chronic spontaneous urticaria: JAMA
A new study published in the Journal of American Medical Association showed that Rilzabrutinib decreased itching and hives ...
Medscape11d
Rilzabrutinib Alleviates Chronic Spontaneous Urticaria Symptoms
Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...
Hosted on MSN1mon
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
SNY's Rilzabrutinib Under Review for Immune Thrombocytopenia Sanofi has developed rilzabrutinib for treating immune thrombocytopenia (“ITP”), another rare, complex autoimmune disorder. A ...
Healio1mon
Rilzabrutinib granted orphan drug designation for IgG4-related disease
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer. There are currently ...
Morningstar1mon
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...